Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitochondrial DNA damage by anticancer agents.

G Singh1, S M Sharkey, R Moorehead

  • 1OCF, Hamilton Regional Cancer Center, Ontario, Canada.

Pharmacology & Therapeutics
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dominant mutation of the murine Hox-2.2 gene results in developmental abnormalities.

The Journal of experimental zoology·1992
Same author

Translocation of aged cyclodiene insecticide residues from soil into forage crops and pastures at various growth stages under field conditions.

Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes·1992
Same author

A quantitative model for spontaneous bone metastasis: evidence for a mitogenic effect of bone on Walker 256 cancer cells.

Clinical & experimental metastasis·1992
Same author

Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone.

Clinical & experimental metastasis·1992
Same author

Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4.

The Journal of biological chemistry·1992
Same author

Gluteal fistula--an unusual manifestation of carcinoma colon.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·1992
Same journal

Protein acetylation modification in tissue fibrosis: Opportunities and challenges.

Pharmacology & therapeutics·2026
Same journal

Nipocalimab and other FcRn blockers in neuromuscular disorders.

Pharmacology & therapeutics·2026
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
Same journal

The neurovascular unit under siege: Molecular mechanisms and potential drug target for cerebral edema.

Pharmacology & therapeutics·2026
See all related articles

Anticancer drugs can damage mitochondrial DNA (mtDNA), potentially impacting cell survival with multiple treatments. Differences in mtDNA levels and protection mechanisms may explain varied drug effects on organs and tumors.

Area of Science:

  • Mitochondrial biology and genetics
  • Cancer therapeutics and pharmacology

Background:

  • Mitochondrial DNA (mtDNA) is vulnerable to damage from various anticancer agents.
  • While minor mtDNA damage is inconsequential, cumulative damage from multiple treatments can significantly affect cell viability.
  • Variations in cellular mtDNA content and mitochondrial protective mechanisms contribute to differential drug toxicity and efficacy.

Purpose of the Study:

  • To explore how anticancer agents interact with mitochondrial DNA (mtDNA).
  • To investigate the role of mtDNA damage in organ-specific toxicities and selective tumor killing by anticancer drugs.
  • To highlight the potential of targeting mitochondria and mtDNA in cancer therapy.

Main Methods:

  • Review and conceptual analysis of existing research on anticancer agents and mitochondrial DNA.

Related Experiment Videos

  • Examination of differential effects based on organ/tumor-specific mitochondrial characteristics.
  • Discussion of current limitations and future research directions in targeting extranuclear DNA.

    • Main Results:

    • Differential mtDNA content and protective mechanisms in various cells can partially explain organ-specific toxicities and tumor selectivity of anticancer agents.
    • Mitochondrial damage, particularly to mtDNA, is a key area of ongoing research for understanding drug mechanisms.
    • Targeting tumor-specific mitochondria or mtDNA remains an attractive but underdeveloped therapeutic strategy.

    Conclusions:

    • Understanding the interaction between anticancer agents and mtDNA is crucial for elucidating mechanisms of drug toxicity and efficacy.
    • Further research into the regulation of mitochondrial genomes in tumor cells is needed to develop targeted therapies.
    • Future investigations will advance knowledge on anticancer agents and extranuclear DNA interactions.